Company · Private
Immunis
Develops an immune-modulating secretome intended to counter age-related muscle and immune decline.
EvidenceEarly
Listing
Private
Ticker
—
Headquarters
Irvine, US
Founded
2019
Technology
Immune secretome therapy
Category
Market cap
Private
Longevity thesis
Restoring immune signalling, not replacing cells, may be the cheaper route to functional benefit.
Pipeline
| Programme | Stage | Focus |
|---|---|---|
| IMMUNA | Phase 1/2 | Muscle atrophy in older adults |
Recent developments
- 3 Jun 2026Reported functional improvement signals in a small cohort.
Scientific evidence
EvidenceEarly
Very small human cohorts; outcomes are function-based and subject to placebo effects.
LONGEFI analysis
Interesting mechanism, weak statistical footing so far. Treat published improvements as hypothesis-generating.
Analysis is research commentary. It is not investment advice or a recommendation.